Skip to content

PTSD: all studies

Page 166 of 210: studies 1,651 to 1,660 of 2,096, newest first. Back to the PTSD overview

Research

Cannabinoid use is enhanced by stress and changes conditioned stress responses.

Neuropsychopharmacology April 2022 Ritchy Hodebourg, Michael E Meyerink, Ayteria D Crow et al.

Individuals diagnosed with post-traumatic stress disorder (PTSD) are often comorbid for substance use disorders. Cannabis is widely used by PSTD patients, and the literature is mixed on whether cannabis use ameliorates or exacerbates patient responses to stress-associated conditioned stimuli (stress-CS). We determined if cannabis use affects responsivity to stress-CS in rats receiving 2 h...

Hallucinogenic drugs and their potential for treating fear-related disorders: Through the lens of fear extinction.

Journal of Neuroscience Research April 1, 2022 Emilija Glavonic, Milos Mitic, Miroslav Adzic 20 citations

Fear-related disorders, mainly phobias and post-traumatic stress disorder, are highly prevalent, debilitating disorders that pose a significant public health problem. They are characterized by aberrant processing of aversive experiences and dysregulated fear extinction, leading to excessive expression of fear and diminished quality of life. The gold standard for treating fear-related disorders...

In silico study of dimethyltryptamine analogues against 5-HT1B receptor: Molecular docking, dynamic simulations and ADMET prediction

Journal of Herbmed Pharmacology April 1, 2022 Neyder Contreras, Antistio Alvíz-amador, Isabella Manzur-Villalobos 5 citations

Introduction: The 5-HT1B receptor has a potential role in various psychiatric disorders such as depression, anxiety, and post-traumatic stress disorder. The objective of this study was to perform docking and molecular dynamics simulation to evaluate at atomic level the behavior of N,N-dimethyltryptamine (DMT) on 5-HT1B receptor.Methods: In this study, initially, a search for DMT was performed...

The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review

Cureus March 30, 2022 Carolina Sepulveda Ramos, Matthew P. Thornburg, Kelly A Long et al. 9 citations

Ketamine, a non-competitive N-methyl-d-aspartate receptor antagonist, is commonly used as an anesthetic and analgesic but has recently shown promising research in treating certain psychiatric conditions such as depression, post-traumatic stress disorder (PTSD), suicidal ideation, and substance use disorder. Due to its euphoric, dissociative, and hallucinogenic properties, ketamine has been...

Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada.

Drug and Alcohol Dependence Reports March 16, 2022 Elena Argento, Shira Goldenberg, Kathleen Deering et al. 6 citations

Background: Psychedelic-assisted therapies are receiving mounting attention for their therapeutic potential. However, little is known about interest among women who experience elevated risk of mental health and substance use disorders. This study examined interest in receiving psychedelic-assisted therapy and socio-structural factors associated with interest among marginalized women. Methods:...

The more mindfulness practice, the more post-trauma stress symptoms? Trait mindfulness and PTSS during the COVID-19 pandemic.

Current Psychology March 15, 2022 Yuzheng Wang, Jing Chen, Xinya Liu et al.

Investigating the contributing factors of post-traumatic stress symptoms (PTSS) has always been an important topic in the field of traumatic psychology research. The current study explored the influences of pandemic/epidemic experiences, meditation experiences, and trait mindfulness on PTSS and the mediating role of emotional resilience during the COVID-19 pandemic. A total of 522 participants...

DOI: 10.1007/s12144-022-02964-9 (opens in new tab) Full text (opens in new tab) Emotional resilience Meditation experiences Post-traumatic stress symptoms Trait mindfulness

Psychedelic Cognition—The Unreached Frontier of Psychedelic Science

Frontiers in Neuroscience March 15, 2022 Maria Bălăeţ 28 citations

Psychedelic compounds hold the promise of changing the face of neuroscience and psychiatry as we know it. There have been numerous proposals to use them to treat a range of neuropsychiatric conditions such as depression, anxiety, addiction and PTSD; and trials to date have delivered positive results in favor of the novel therapeutics. Further to the medical use, the wider healthy population is...

Behavioral Psychedelics: Integrating Mind and Behavior to Improve Health and Resilience

Frontiers in Psychiatry March 14, 2022 Edmund C. Neuhaus, George M. Slavich 14 citations

One of the most recent and potentially promising advancements in the health sciences has involved the attempted use of psychedelics for treating mental and behavioral health problems, such as anxiety, depression, posttraumatic stress disorder, and addiction. Despite surging scientific and public interest in this work, however, we presently have no standard of care or consensus regarding how...

DOI: 10.3389/fpsyt.2022.821208 (opens in new tab) Anxiety Mental health Psychotherapist Public health +1

Effectiveness of Mantra-Based Meditation on Mental Health: A Systematic Review and Meta-Analysis.

International Journal of Environmental Research and Public Health March 13, 2022 Yolanda Álvarez-Pérez, Amado Rivero-Santana, Lilisbeth Perestelo-Pérez et al.

Meditation is defined as a form of cognitive training that aims to improve attentional and emotional self-regulation. This systematic review aims to evaluate the available scientific evidence on the effectiveness and safety of mantra-based meditation techniques (MBM), in comparison to passive or active controls, or other active treatment, for the management of mental health symptoms. MEDLINE,...

DOI: 10.3390/ijerph19063380 (opens in new tab) Full text (opens in new tab) Mantra-based meditation Mental health Meta-analysis Systematic review

A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders

Australian & New Zealand Journal of Psychiatry March 12, 2022 Steve Kisely, Mark Connor, Andrew A Somogyi et al. 36 citations

Objectives: There is an increasing interest in combining psilocybin or methylenedioxymethamphetamine with psychological support in treating psychiatric disorders. Although there have been several recent systematic reviews, study and participant numbers have been limited, and the field is rapidly evolving with the publication of more studies. We therefore conducted a systematic review of PubMed,...